What is Accelevir Diagnostics?
Accelevir Diagnostics operates as a CLIA-certified central laboratory and contract research organization (CRO) with a specialized focus on virology and immunology services. The company offers a comprehensive suite of expert clinical study services, encompassing molecular and genomic analysis, advanced immunology assays, and integrated virology-immunology workflows. Accelevir aims to serve academic institutions, government programs, and commercial entities engaged in cell and gene therapies, oncology, and infectious diseases. Their commitment lies in advancing innovative assays and technologies to bolster biomarker-informed clinical trials and accelerate therapeutic development.
How much funding has Accelevir Diagnostics raised?
Accelevir Diagnostics has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
Key Investors in Accelevir Diagnostics
PPP
Public-Private Partnership
What's next for Accelevir Diagnostics?
With substantial expansion capital secured, Accelevir Diagnostics is poised for significant operational scaling and technological advancement. The company's strategic focus on virology and immunology services, coupled with its CLIA certification, positions it to capitalize on the growing demand for specialized CRO support in complex therapeutic areas like cell and gene therapy and infectious diseases. Future investments will likely target enhancing laboratory capacity, expanding assay development capabilities, and potentially broadening its service offerings to meet the evolving needs of its client base in academic, governmental, and commercial sectors. This funding injection is expected to accelerate their contribution to biomarker-informed clinical trials and the development of novel therapeutics.
See full Accelevir Diagnostics company page
